GOELAMS with final results after a median follow-up of 9 years advanced follicular lymphoma: a randomized multicenter study by the transplantation and doxorubicin-based chemotherapy in patients with High-dose therapy followed by autologous purged stem cell

doi:10.1182/blood-2008-05-160200Prepublished online October 27, 2008;2009 113: 995-1001€€€€Molucon-Chabrot, Roselyne Delepine, Noel Milpied, Philippe Colombat and Eric DeconinckBernard Desablens, Jerome Jaubert, Jean-Francois Ramee, Nina Arakelyan, Antoine Thyss, CecileBerthou, Herve Maisonneuve, Vincent Delwail, Remi Gressin, Philippe Quittet, Jean-Pierre Vilque, Emmanuel Gyan, Charles Foussard, Philippe Bertrand, Patrick Michenet, Steven Le Gouill, Christian€

[1]  A. Levis,et al.  Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. , 2008, Blood.

[2]  N. Schmitz,et al.  Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study , 2007, Leukemia.

[3]  J. Gribben,et al.  Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Salles,et al.  Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2006, Blood.

[6]  T. Habermann,et al.  Absolute lymphocyte count predicts overall survival in follicular lymphomas , 2006, British journal of haematology.

[7]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[8]  R. Gressin,et al.  High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. , 2005, Blood.

[9]  R. Gressin,et al.  Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[11]  H. Lazarus,et al.  Stem cell transplantation in follicular lymphoma: progress at last? , 2004, Bone Marrow Transplantation.

[12]  G. Salles,et al.  Rituximab Added αIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients. , 2004 .

[13]  V. Diehl,et al.  Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. , 2004, Blood.

[14]  S. Markovic,et al.  Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation , 2004, Clinical and Experimental Medicine.

[15]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[16]  J. Gibson,et al.  Low-grade lymphoma: the optimal timing. , 2004, Transplantation proceedings.

[17]  M. Boccadoro,et al.  Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Gaulard,et al.  Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Ruta Bajorunaite,et al.  Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.

[20]  M. Sydes,et al.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Dispenzieri,et al.  Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma , 2003, Bone Marrow Transplantation.

[22]  A. Cuzzocrea,et al.  Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab , 2003, Bone Marrow Transplantation.

[23]  M. Herold,et al.  Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab , 2003, Annals of Hematology.

[24]  N. Ifrah,et al.  Intensive therapies in follicular non-Hodgkin lymphomas. , 2002, Blood.

[25]  L. Arcaini,et al.  A sequence of immuno‐chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high‐dose chemotherapy and autotransplant is an effective 
and non‐toxic treatment for advanced follicular 
and mantle cell lymphoma , 2002, British journal of haematology.

[26]  R. Bouabdallah,et al.  High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  E. Deconinck,et al.  Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study , 2000, Bone Marrow Transplantation.

[28]  J. Gribben,et al.  Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. , 1999, Blood.

[29]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Rossi,et al.  Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Horning,et al.  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.

[33]  A. Norton,et al.  Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Coiffier,et al.  Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. , 1994, Bone marrow transplantation.

[35]  B. Coiffier,et al.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.

[36]  J. Gribben,et al.  Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. , 1991, The New England journal of medicine.

[37]  A. H. T. Robb-Smith,et al.  U.S. NATIONAL CANCER INSTITUTE WORKING FORMULATION OF NON-HODGKIN'S LYMPHOMAS FOR CLINICAL USE , 1982, The Lancet.

[38]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[39]  P. Zinzani,et al.  Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. , 2005, Haematologica.

[40]  C. Bloomfield,et al.  Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Salles,et al.  Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. , 2001, Blood.